STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] SOPHiA GENETICS SA SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) filing a Form 144 notifies a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51 to be sold approximately on 10/03/2025 on NASDAQ. The shares were acquired as Restricted Stock Units on 10/02/2025 from the issuer and payment was recorded on 10/02/2025. The filing shows the seller previously completed Rule 10b5-1 sales totaling 5,337 shares across five transactions from 07/07/2025 through 09/19/2025, generating gross proceeds shown per transaction. The Form 144 includes the seller's representation that no undisclosed material adverse information exists and conforms to Rule 144 disclosure requirements.

Positive
  • Compliance with Rule 144 filing for proposed sale of 6,833 shares (aggregate $30,543.51)
  • Acquisition documented as Restricted Stock Units on 10/02/2025, showing clear basis for sale eligibility
Negative
  • Insider selling activity: prior Rule 10b5-1 sales of 5,337 shares between 07/07/2025 and 09/19/2025
  • Sale size relative to outstanding shares: 6,833 vs 67,579,560 outstanding (small but disclosed insider liquidation)

Insights

TL;DR: Insider intends to sell newly vested 6,833 RSU shares worth $30,543.51 on or about 10/03/2025.

The filing discloses that the securities were acquired as Restricted Stock Units on 10/02/2025, indicating a recent vesting or issuance event explicitly documented in the notice. The planned sale is being reported under Rule 144, which is the standard compliance path for restricted or control securities becoming eligible for public sale.

The archive of Rule 10b5-1 sales shows the same account sold 5,337 shares in five transactions between 07/07/2025 and 09/19/2025, with per-transaction gross proceeds listed in the filing. That history confirms recent, disclosed offloading activity by the same holder.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What is the amount of SOPH shares proposed for sale in the Form 144?

The Form 144 reports a proposed sale of 6,833 common shares with an aggregate market value of $30,543.51.

When were the shares to be sold acquired according to the filing?

The shares were acquired as Restricted Stock Units on 10/02/2025, with payment recorded on the same date.

On what date is the planned sale scheduled?

The approximate date of sale listed is 10/03/2025 on NASDAQ.

Does the filing show prior sales by the same person?

Yes. The filing lists five Rule 10b5-1 sales totaling 5,337 shares between 07/07/2025 and 09/19/2025, with gross proceeds per transaction disclosed.

What assurance does the seller provide about undisclosed information?

By signing the notice, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Sophia Genetics Sa

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Latest SEC Filings

SOPH Stock Data

277.49M
63.48M
6.46%
48.2%
0.06%
Health Information Services
Healthcare
Link
Switzerland
Rolle